229 related articles for article (PubMed ID: 34990833)
1. Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis.
Wang P; Wang S; Li X; Lin G; Ma Y; Xiao R; Li H; Qiu M; Yang F
Int J Surg; 2022 Jan; 97():106206. PubMed ID: 34990833
[TBL] [Abstract][Full Text] [Related]
2. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
3. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.
Jin SB; Tian ZB; Ding XL; Guo YJ; Mao T; Yu YN; Wang KX; Jing X
Front Oncol; 2021; 11():619592. PubMed ID: 34249675
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer.
Kudou K; Saeki H; Nakashima Y; Edahiro K; Korehisa S; Taniguchi D; Tsutsumi R; Nishimura S; Nakaji Y; Akiyama S; Tajiri H; Nakanishi R; Kurashige J; Sugiyama M; Oki E; Maehara Y
Ann Surg Oncol; 2017 Jul; 24(7):1804-1810. PubMed ID: 28224363
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
8. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer.
Mayanagi S; Tsubosa Y; Omae K; Niihara M; Uchida T; Tsushima T; Yokota T; Sato H; Naito T; Yasui H
Ann Surg Oncol; 2017 Nov; 24(12):3741-3747. PubMed ID: 28861809
[TBL] [Abstract][Full Text] [Related]
9. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
[TBL] [Abstract][Full Text] [Related]
10. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
11. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
[TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection.
West MA; Baker WC; Rahman S; Munro A; Jack S; Grocott MP; Underwood TJ; Levett DZ;
J Surg Oncol; 2021 Dec; 124(8):1306-1316. PubMed ID: 34463378
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
14. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
[TBL] [Abstract][Full Text] [Related]
15. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
[TBL] [Abstract][Full Text] [Related]
17. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical outcomes of sarcopenia in patients with esophageal, gastric or colorectal cancers receiving preoperative neoadjuvant therapy: A meta-analysis.
Luo L; Fan Y; Wang Y; Wang Z; Zhou J
Asia Pac J Oncol Nurs; 2024 Apr; 11(4):100436. PubMed ID: 38618524
[TBL] [Abstract][Full Text] [Related]
20. Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis.
Jogiat UM; Bédard ELR; Sasewich H; Turner SR; Eurich DT; Filafilo H; Baracos V
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2630-2636. PubMed ID: 36151845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
